Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,518 total articles

Jefferies Starts Coverage on Cellectis, Assigns Buy and $7 Target

Jefferies Starts Coverage on Cellectis, Assigns Buy and $7 Target

Jefferies has initiated coverage of Cellectis (NASDAQ:CLLS) with a Buy rating and a $7.00 price objective, representing an 88% uplift from the stock's current level of $3.73. The firm characterizes the company as "largely overlooked" given an enterprise value near $60 million, even as Cellectis has posted robust revenue growth and demonstrated enco…

UBS Elevates Melco Resorts to Buy Despite Tighter Price Target

UBS Elevates Melco Resorts to Buy Despite Tighter Price Target

UBS raised its rating on Melco Resorts & Entertainment Ltd. from Neutral to Buy while trimming its price objective to $9.50 from $9.80. The bank cited expected benefits from ongoing enhancements at City of Dreams in Macau and projected strong free cash flow in 2026-2027, even as investors contend with trademark licensing fee increases, margin press…

TD Cowen Lifts Applied Materials Price Target to $450, Citing Systems Growth and Process Intensity

TD Cowen Lifts Applied Materials Price Target to $450, Citing Systems Growth and Process Intensity

TD Cowen increased its price target on Applied Materials to $450 from $315 and maintained a Buy rating, aligning with the highest analyst target for the stock. The firm emphasized Applied Materials' exposure to potential semiconductor systems growth — roughly 20% in calendar 2026 as implied by Applied Materials and Lam Research — and highlighted dr…

Canaccord Lowers Artivion Price Target to $48, Keeps Buy Rating Citing Market Multiple Compression

Canaccord Lowers Artivion Price Target to $48, Keeps Buy Rating Citing Market Multiple Compression

Canaccord Genuity cut its price target on Artivion Inc. (AORT) to $48 from $51 but maintained a Buy rating, citing compressed valuation multiples across comparable groups during the recent market downturn. The new target implies roughly 26% upside from the current share price of $38. Artivion reported stronger-than-expected adjusted Q4 revenue and …